Destiny Pharma PLC Notice to Register for 2021 AGM (0577Z)
May 19 2021 - 1:00AM
UK Regulatory
TIDMDEST
RNS Number : 0577Z
Destiny Pharma PLC
19 May 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Notice to Register for 2021 AGM
Brighton, United Kingdom - 19 May 2021 - Destiny Pharma plc
(AIM: DEST) a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent
life-threatening infections, as announced on 4 May 2021, will hold
its 2021 Annual General Meeting ("AGM") at the offices of finnCap
Ltd, Destiny Pharma's Nominated Advisor and Joint Broker, at
11.00am BST on 3 June 2021. Destiny Pharma will operate an audio
dial-in facility to allow Shareholders to listen to the business of
the meeting.
As previously announced in the Posting of Annual Report and
Notice of AGM , whilst in normal circumstances the Board values the
opportunity to engage with shareholders in person at its AGM, on
this occasion the Board feels it is appropriate to advise
shareholders against travelling to attend the AGM in person and,
instead, to submit proxy votes as early as possible because, as
matters currently stand, shareholders will not be granted access to
the AGM. Shareholders are strongly advised to appoint the Chairman
of the AGM as their proxy.
Immediately following the AGM at 11:00am BST, Destiny Pharma
will host a live webcast presentation followed by Q&A.
Shareholders will not get an opportunity to vote or ask
questions or any other participation during the call but are
encouraged to pre-submit any questions for Directors of the Company
in advance of the AGM to agm2021@destinypharma.com by no later than
17:00pm BST on 2 June, 2021. Please include the Shareholder's name
and Shareholder Reference Number (which can be found on the share
certificate or proxy form) in your email.
A full recording of the 2021 AGM will be made available on the
Company's website at www.destinypharma.com
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com
finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information on the company, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STRAPMRTMTIBBTB
(END) Dow Jones Newswires
May 19, 2021 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024